Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant

Chemico-Biological Interactions

Volumn 220, Issue , 2014, Pages 222-230

  Evers, Nynke M ^a   Wang, Si ^a   Van Den Berg, Johannes H J ^a   Houtman, René ^b   Melchers, Diana ^b   De Haan, Laura H J ^a   Ederveen, Antwan G H ^c   Groten, John P ^a,b   Rietjens, Ivonne M C M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b PamGene International BV   (Netherlands)

^c MSD   (Netherlands)

Author keywords

4 hydroxytamoxifen; ER ; ER ; fulvestrant; MARCoNI; U2OS reporter gene assay

Indexed keywords

AFIMOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; ESTROGEN RECEPTOR; HYDROXYTAMOXIFEN; PROTEIN BINDING; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; MODULATION; REPORTER GENE; U2OS CELL LINE; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; MICROARRAY ANALYSIS;

CELL LINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; GENE EXPRESSION REGULATION; HUMANS; INHIBITORY CONCENTRATION 50; MICROARRAY ANALYSIS; PROTEIN BINDING; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84904993615     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.06.019     Document Type: Article

References (53)

1. B.S. Katzenellenbogen, I. Choi, R. Delage-Mourroux, T.R. Ediger, P.G. Martini, M. Montano, J. Sun, K. Weis, and J.A. Katzenellenbogen Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology J. Steroid Biochem. Mol. Biol. 74 5 2000 279 285 (Pubitemid 32126240)
2. S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.Å. Gustafsson Mechanisms of estrogen action Physiol. Rev. 81 4 2001 1535 1565 (Pubitemid 32951806)
3. J.Å. Gustafsson Estrogen receptor beta - a new dimension in estrogen mechanism of action J. Endocrinol. 163 3 1999 379 383
4. P. Sismondi, N. Biglia, R. Ponzone, L. Fuso, C. Scafoglio, L. Cicatiello, M. Ravo, A. Weisz, D. Cimino, G. Altobelli, O. Friard, and M. De Bortoli Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes Maturitas 57 1 2007 50 55 (Pubitemid 46602892)
5. J.M. Hall, and D.P. McDonnell Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting Mol. Interv. 5 6 2005 343 357 (Pubitemid 43060715)
6. J.D. Norris, D. Fan, A. Sherk, and D.P. McDonnell A negative coregulator for the human ER Mol. Endocrinol. 16 3 2002 459 468 (Pubitemid 34214566)
7. A.M. Sotoca, J.H.J. van den Berg, J. Vervoort, P.T. van der Saag, A. Ström, J.Å. Gustafsson, I.M.C.M. Rietjens, and A.J. Murk Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells Toxicol. Sci. 105 2 2008 303 311
8. A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer Endocr. Relat. Cancer 13 3 2006 689 706 (Pubitemid 44763252)
9. D.C. Mendelssohn Coping with the CKD epidemic: the promise of multidisciplinary team-based care Nephrol. Dial. Transpl. 20 1 2005 10 12 (Pubitemid 40207601)
10. N.M. Evers, T.M.C. van de Klundert, Y.M. van Aesch, S. Wang, W.K. de Roos, A. Romano, L.H.J. de Haan, A.J. Murk, A.G.H. Ederveen, I.M.C.M. Rietjens, and J.P. Groten Human T47D-ERbeta breast cancer cells with tetracycline- dependent ERbeta expression reflect ERalpha/ERbeta ratios in rat and human breast tissue Toxicol. In Vitro 27 6 2013 1753 1761
11. H.A. Harris Estrogen receptor-beta: recent lessons from in vivo studies Mol. Endocrinol. 21 1 2007 1 13 (Pubitemid 46041687)
12. A. Bardin, N. Boulle, G. Lazennec, F. Vignon, and P. Pujol Loss of ERbeta expression as a common step in estrogen-dependent tumor progression Endocr. Relat. Cancer 11 3 2004 537 551 (Pubitemid 39331282)
13. F. Stossi, D.H. Barnett, J. Frasor, B. Komm, C.R. Lyttle, and B.S. Katzenellenbogen Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors Endocrinology 145 7 2004 3473 3486 (Pubitemid 38830020)
14. A. Ström, J. Hartman, J.S. Foster, S. Kietz, J. Wimalasena, and J.Å. Gustafsson Estrogen receptor beta inhibits 17beta-estradiol- stimulated proliferation of the breast cancer cell line T47D Proc. Natl. Acad. Sci. U.S.A. 101 6 2004 1566 1571 (Pubitemid 38236167)
15. A.M. Sotoca, D. Ratman, P.T. van der Saag, A. Ström, J.Å. Gustafsson, J. Vervoort, I.M.C.M. Rietjens, and A.J. Murk Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio J. Steroid Biochem. Mol. Biol. 112 4-5 2008 171 178
16. J. Zhu, S. Sen, C. Wei, and M.L. Frazier Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription Int. J. Oncol. 36 1 2010 39 48
17. N.M. Evers, S. Boeren, J.H.J. van den Berg, J.P. Groten, I.M.C.M. Rietjens, and J. Vervoort Quantitative Proteomics Addressing the Estrogen Receptor Subtype-Mediated Effects in T47D Breast Cancer Cells Exposed to 4-Hydroxytamoxifen PhD thesis, N.M. Evers, Factors influening ER subype-mediated cell prolieration and apoptosis 2014 Wageningen University Wageningen 107 172
18. P.G. Toniolo, M. Levitz, A. Zeleniuch-Jacquotte, S. Banerjee, K.L. Koenig, R.E. Shore, P. Strax, and B.S. Pasternack A prospective study of endogenous estrogens and breast cancer in postmenopausal women J. Natl. Cancer Inst. 87 3 1995 190 197
19. D.A. Berry, C. Cirrincione, I.C. Henderson, M.L. Citron, D.R. Budman, L.J. Goldstein, S. Martino, E.A. Perez, H.B. Muss, L. Norton, C. Hudis, and E.P. Winer Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer J. Am. Med. Assoc. 295 14 2006 1658 1667
20. M. Dutertre, and C.L. Smith Molecular mechanisms of selective estrogen receptor modulator (SERM) action J. Pharmacol. Exp. Ther. 295 2 2000 431 437
21. S. Grilli Tamoxifen (TAM): the dispute goes on Annali dell'Istituto superiore di sanita 42 2 2006 170 173 (Pubitemid 44562794)
22. A.U. Buzdar Fulvestrant - a novel estrogen receptor antagonist for the treatment of advanced breast cancer Drugs Today 44 9 2008 679 692
23. A. Howell, J.F. Robertson, P. Abram, M.R. Lichinitser, R. Elledge, E. Bajetta, T. Watanabe, C. Morris, A. Webster, I. Dimery, and C.K. Osborne Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J. Clin. Oncol. 22 9 2004 1605 1613 (Pubitemid 41079798)
24. I.A. Jaiyesimi, A.U. Buzdar, D.A. Decker, and G.N. Hortobagyi Use of tamoxifen for breast cancer: twenty-eight years later J. Clin. Oncol. 13 2 1995 513 529
25. D.L. Metzger, and J.R. Kerrigan Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence J. Clin. Endocrinol. Metab. 79 2 1994 513 518 (Pubitemid 24256545)
26. P. Rouanet, D. Drouin, J. Wepierre, Prevention and treatment of breast cancer with 4-hydroxytamoxifen, patent 20090186944 A1, 2009.
27. C.S. Murphy, S.M. Langan-Fahey, R. McCague, and V.C. Jordan Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro Mol. Pharmacol. 38 5 1990 737 743
28. A. Zou, K.B. Marschke, K.E. Arnold, E.M. Berger, P. Fitzgerald, D.E. Mais, and E.A. Allegretto Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen Mol. Endocrinol. 13 3 1999 418 430 (Pubitemid 29113874)
29. C.K. Osborne, A. Wakeling, and R.I. Nicholson Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action Br. J. Cancer 90 Suppl. 1 2004 S2 6
30. A.E. Wakeling, M. Dukes, and J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res. 51 15 1991 3867 3873
31. J.F. Robertson, R.I. Nicholson, N.J. Bundred, E. Anderson, Z. Rayter, M. Dowsett, J.N. Fox, J.M. Gee, A. Webster, A.E. Wakeling, C. Morris, and M. Dixon Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer Cancer Res. 61 18 2001 6739 6746 (Pubitemid 32896496)
32. D. Lymperatou, E. Giannopoulou, A.K. Koutras, and H.P. Kalofonos The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently BioMed Res. Int. 2013 2013 147514
33. J.F. Robertson Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective Cancer Treat. Rev. 30 8 2004 695 706 (Pubitemid 39497155)
34. L. Zhao, C. Jin, Z. Mao, M.B. Gopinathan, K. Rehder, and R.D. Brinton Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator - a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons J. Med. Chem. 50 18 2007 4471 4481 (Pubitemid 47378843)
35. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Ström, E. Treuter, M. Warner, and J.Å. Gustafsson Estrogen receptors: how do they signal and what are their targets Physiol. Rev. 87 3 2007 905 931 (Pubitemid 47084672)
36. T.N. Collingwood, F.D. Urnov, and A.P. Wolffe Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription J. Mol. Endocrinol. 23 3 1999 255 275 (Pubitemid 30055983)
37. N.M. Evers, J.H.J. van den Berg, S. Wang, D. Melchers, R. Houtman, L.H.J. de Haan, A.G.H. Ederveen, J.P. Groten, and I.M.C.M. Rietjens Cell Proliferation and Modulation of Interaction of Estrogen Receptors with Co-regulators Induced by Selective ERα and ERβ Agonists J. Steroid Biochem. Mol. Biol. 143 2014 376 385
38. J.F. Glover, J.T. Irwin, and P.D. Darbre Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-1 and T-47-D Cancer Res. 48 13 1988 3693 3697
39. M.E. Quaedackers, C.E. Van Den Brink, S. Wissink, R.H. Schreurs, J.Å. Gustafsson, P.T. Van Der Saag, and B.B. Van Der Burg 4-Hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta Endocrinology 142 3 2001 1156 1166 (Pubitemid 32203725)
40. H.L. Jeanes, C. Tabor, D. Black, A.G.H. Ederveen, and G.A. Gray Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)alpha agonist and unaffected by an ER beta antagonist J. Endocrinol. 197 3 2008 493 501 (Pubitemid 351803954)
41. D.M. Attia, and A.G.H. Ederveen Opposing roles of ERalpha and ERbeta in the genesis and progression of adenocarcinoma in the rat ventral prostate Prostate 72 9 2012 1013 1022
42. M.S. Malamas, E.S. Manas, R.E. McDevitt, I. Gunawan, Z.B. Xu, M.D. Collini, C.P. Miller, T. Dinh, R.A. Henderson, J.C. Keith Jr., and H.A. Harris Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands J. Med. Chem. 47 21 2004 5021 5040 (Pubitemid 39314900)
43. M.G.R. ter Veld, B. Schouten, J. Louisse, D.S. van Es, P.T. van der Saag, I.M.C.M. Rietjens, and A.J. Murk Estrogenic potency of food-packaging- associated plasticizers and antioxidants as detected in ERalpha and ERbeta reporter gene cell lines J. Agric. Food Chem. 54 12 2006 4407 4416 (Pubitemid 44013348)
44. R. Houtman, R. de Leeuw, M. Rondaij, D. Melchers, D. Verwoerd, R. Ruijtenbeek, J.W.M. Martens, J. Neefjes, and R. Michalides Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen Mol. Cancer Ther. 11 4 2012 805 816
45. J.M.M.J.G. Aarts, S. Wang, R. Houtman, R.M.G.J. van Beuningen, W.M.A. Westerink, B.J. Van De Waart, I.M.C.M. Rietjens, and T.F.H. Bovee Robust array-based coregulator binding assay predicting ERalpha-agonist potency and generating binding profiles reflecting ligand structure Chem. Res. Toxicol. 26 3 2013 336 346
46. C.L. Smith, Z. Nawaz, and B.W. O'Malley Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol. Endocrinol. 11 6 1997 657 666 (Pubitemid 27225293)
47. G.J. Bates, S.M. Nicol, B.J. Wilson, A.M. Jacobs, J.C. Bourdon, J. Wardrop, D.J. Gregory, D.P. Lane, N.D. Perkins, and F.V. Fuller-Pace The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor EMBO J. 24 3 2005 543 553 (Pubitemid 40343256)
48. C. Ambrosino, R. Tarallo, A. Bamundo, D. Cuomo, G. Franci, G. Nassa, O. Paris, M. Ravo, A. Giovane, N. Zambrano, T. Lepikhova, O.A. Janne, M. Baumann, T.A. Nyman, L. Cicatiello, and A. Weisz Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei Mol. Cell. Proteomics 9 6 2010 1352 1367
49. M. Ivanova, S. Abner, W. Pierce Jr., and C. Klinge Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses Proteome Sci. 9 1 2011 60
50. S. Wang, R. Houtman, D. Melchers, J.M.M.J.G. Aarts, A.A.C.M. Peijnenburg, R.M.G.J. van Beuningen, I.M.C.M. Rietjens, and T.F.H. Bovee A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds ALTEX 30 2 2013 145 157
51. L.E. Shaw, A.J. Sadler, D. Pugazhendhi, and P.D. Darbre Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells J. Steroid Biochem. Mol. Biol. 99 1 2006 19 32
52. G. Reid, M.R. Hübner, R. Métvier, H. Brand, S. Denger, D. Manu, J. Beaudouin, J. Ellenberg, and F. Gannon Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling Mol. Cell 11 3 2003 695 707 (Pubitemid 36385123)
53. A.U. Buzdar Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer Drugs Today 40 9 2004 751 764 (Pubitemid 39482304)